APC Med

APC Medicine is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of innovative RNA-based therapeutics. The company focuses on leveraging its proprietary tRNA and mRNA platforms to address diseases caused by nonsense mutations, which account for a significant portion of genetic disorders and cancers. APC Medicine's lead programs utilize suppressor tRNA technology to read through premature stop codons, potentially restoring the production of full-length, functional proteins. With a robust pipeline targeting oncology and rare genetic conditions, the company aims to provide transformative treatments for patients with high unmet medical needs. The company is backed by leading life science investors including Lilly Asia Ventures and Hillhouse Capital.